TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06641609: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of CFT8919 Capsules in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

Sponsor: Betta Pharmaceuticals Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 166 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06641609 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06641609 Rescue Dossier →